Catalyst Pharm reports Q3 diluted EPS (9c) vs. consensus of (11c)
As a development stage biopharmaceutical company, Catalyst has no revenues to-date. At September 30, 2009, the Company had cash and cash equivalents totaling $4.9M and no long-term debt. :theflyonthewall.com
News For CPRX From The Last 14 Days
Check below for free stories on CPRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
